Apollomics (Nasdaq: APLM) entered into definitive subscription agreements for a $10.0 million private placement with accredited investors. The transaction is expected to close on or about August 14, 2026, subject to customary conditions.The private placement includes cash subscriptions for 533,334 Class A shares at $15.00 per share, for gross cash proceeds of about $8.0 million, and the automatic conversion of a $2.0 million unsecured convertible promissory note held by CEO Hung-Wen (Howard) Chen into 166,667 Class A shares at $12.00 per share. Certain executive officers and directors or their affiliates are participating in the cash portion. No placement agents or underwriters are involved, and no finder's fees or commissions are payable. The shares will be issued as unregistered, restricted securities under exemptions including Section 4(a)(2) and Rule 506 of Regulation D.

Reported Friday, Jul 17 - 9:52am EDT (TheFly subscription required to read more.)

Reported Friday, Jul 17 - 9:47am EDT (TheFly subscription required to read more.)

Reported Monday, Jul 13 - 9:18am EDT (TheFly subscription required to read more.)

Nasdaq staff notified Apollomics on July 8 that its market value of listed securities met the $35M Rule 5550(b)(2) minimum for 10 straight days, closing the matter.

Reported Thursday, Jun 25 - 11:55am EDT (TheFly subscription required to read more.)

Reported Thursday, Jun 25 - 11:50am EDT (TheFly subscription required to read more.)

Reported Wednesday, Jun 24 - 4:31pm EDT (TheFly subscription required to read more.)

Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that

Apollomics (Nasdaq: APLM) reported full-year 2025 results and clinical updates on April 27, 2026. Key corporate facts: cash and equivalents $3.3M at December 31, 2025; 2025 revenue $8.5M (up from $0 in 2024) largely from an upfront licensing payment; and net loss $10.9M for 2025.Clinical progress centers on vebreltinib (APL-101): NMPA approvals in China for three indications, ongoing global Phase 2 SPARTA study (282+ enrolled) and planned U.S. IND submission for accelerated approval in H1 2027 for NSCLC with c-MET amplification, per the company.

Apollomics raised $2.0M in a CEO-provided bridge loan reported Apr 1, 2026; terms were not disclosed and the facility likely covers only short-term runway.

Apollomics (Nasdaq: APLM) entered a $2.0 million unsecured convertible promissory note with CEO Hung-Wen (Howard) Chen on March 30, 2026 to provide working capital for clinical development and general operations.The Note bears 0% interest and will automatically convert upon a subsequent equity financing of at least $10.0 million at a 20% discount to that financing's lowest per-share price. The independent Audit Committee and Board approved the related-party terms, with the CEO abstaining from the vote.

Reported Monday, Mar 9 - 5:18pm EDT (TheFly subscription required to read more.)

Reported Tuesday, Dec 30 - 4:00pm EST (TheFly subscription required to read more.)

Reported Tuesday, Dec 30 - 3:51pm EST (TheFly subscription required to read more.)